A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2026-05-19
• Target enrollment: 0
• Participant gender: All

Summary

INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tallac Therapeutics

Criteria

Inclusion Criteria:

1. Histologically or cytologically-documented solid tumors.

2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

3. Demonstrate adequate organ function.

Exclusion Criteria:

1. Prior history of or active malignant disease other than that being treated in this study.

2. Known brain metastases or cranial epidural disease.

3. A known hypersensitivity to the components of the study therapy or its' analogs.